Tumor homology with self as a biomarker for response to checkpoint inhibitor therapy

by Elena Iemma | Nov 17, 2022

EpiVaxTx_SITC22_Melanoma_28Oct22_56Wx31.5H    

Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy

by Elena Iemma | Dec 9, 2021

Multi-step screening of neoantigens’ HLA- and TCR-interfaces improves prediction of survival

by Elena Iemma | May 13, 2021

From infectious disease to personalized cancer vaccines: Regulatory T cell epitopes determine patient outcomes and suppress neoantigen responses

by Annie De Groot | Nov 6, 2018

EpiVax_Oncology_Ancer_SITC_05Nov18_39Wx35H

Disease Status Explained by Neo-epitopes with Low Potential for Activating Regulatory T cells: an Application of Precision Cancer Immunotherapy Design Tools to Bladder Cancer

by Annie De Groot | Oct 8, 2018

EpiVax_poster_Disease Status Explained by Neo-Epitopes with Low Potential for Activating Regulatory T Cells